Drugs / Radioiodine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00196729 | Dec 2001 → Sep 2003 | thyroid tumor | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04354324 | Apr 2020 → Jun 2024 | thyroid gland papillary carcinoma | Zhujiang Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radioiodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04354324 ↗ |
| Known as | 131I | “All patients received the same amount of radioactive iodine (100 mCi or 3.7 GBq of 131I).” NCT00196729 ↗ |
| Route | Oral | “followed by oral radioiodine” NCT00196729 ↗ |